kabutan

Cyfuse Biomedical K.K.(4892) Summary

4892
TSE Growth
Cyfuse Biomedical K.K.
517
JPY
-13
(-2.45%)
Dec 12, 3:30 pm JST
3.31
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
1.79
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
530 JPY 3.40 USD
Previous Close Dec 11
530 JPY 3.39 USD
High Dec 12, 9:04 am
531 JPY 3.41 USD
Low Dec 12, 2:05 pm
516 JPY 3.31 USD
Volume
72,500
Trading Value
0.04B JPY 0.24M USD
VWAP
521.34 JPY 3.35 USD
Minimum Trading Value
51,700 JPY 331 USD
Market Cap
4.97B JPY 0.03B USD
Number of Trades
214
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Slightly High
1-Year Average
742
1-Year High Feb 13, 2025
14,682
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 0 1,037,600
Nov 28, 2025 0 1,028,900
Nov 21, 2025 0 1,048,500
Nov 14, 2025 700 1,102,600 1575.14
Nov 7, 2025 0 1,119,000
Company Profile
Cyfuse Biomedical K.K. engages in the development, manufacturing, and sales of regenerative medicine products using bio 3D printers.
Sector
Pharmaceuticals
Cyfuse Biomedical K.K. primarily focuses on the development, manufacturing, and sales of regenerative medicine products using bio 3D printers, while expanding its multifaceted business across three domains: regenerative medicine, drug discovery support, and devices. In the regenerative medicine field, the company develops new regenerative medicine products by creating three-dimensional tissues and organs made solely from cells, advancing multiple pipelines such as peripheral nerve regeneration and bone and cartilage regeneration. In the drug discovery support area, Cyfuse offers contract research services for cell products and develops and sells new 3D cell products like organ models. In the device domain, the company develops and sells bio 3D printers, applies technologies necessary for cell product development, and creates new technologies. Through its proprietary core technology and strategic partnerships, Cyfuse Biomedical K.K. aims to realize innovative regenerative medicine products.